ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements
PDPics / Pixabay

ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements

  Have you ever heard of Orphan Drug designation? This designation, granted by the U.S. Food and Drug Administration (FDA), is given to drugs or biologics that are designed to treat,…

Continue Reading ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements